Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

Austria
France
Germany
Rare-G
The Epidermal Growth Factor System in Rare Glomerular Disease: From Molecular Mechanisms to Therapeutics

Project Coordinator

Division of Nephrology and Immunology University Hospital of the Aachen Technical University (RWTH)
Aachen
Germany

Partners

Dontscho Kerjaschki Chair of the Department of Pathology Medical University of Vienna Vienna, Austria
Nicole Endlich Anatomy and Cell Biology Ernst Moritz Arndt University Greifswald, Germany
Pierre-Louis Tharaux PARCC, INSERM and Université Paris-Descartes Paris, France

Glomerular diseases are rare diseases. Nevertheless, they often lead to chronic renal failure and lifelong renal replacement therapy. We have shown, that in two forms of glomerular diseases, i.e. rapidly progressive glomerulonephritis (RPGN) and primary focal and segmental glomerulosclerosis (FSGS), glomerular epithelial cells get activated and that this results in loss of renal function. In addition, we have strong evidence that the epidermal growth factor (EGF) system is one of the major signaling pathways mediating activation of glomerular epithelial cells. In the present proposal, we will analyze the EGF system in vivo and in primary cells. We will use knock-out mouse models to analyze the relevance of the EGF system within glomerular cells. In a basic science approach, novel targets within the EGF system will be investigated. Regarding FSGS, we have identified a role of microRNA193 in podocytes. For RPGN, we will investigate cellular bridge formation, a crucial event in the disease. For the transition of pharmacological EGF inhibition to the clinical application, we will test in a macaque model of RPGN a novel recombinant decoy receptor against HB-EGF to reduce toxic side effects. For FSGS, the EGF system will be inhibited in an established rat model using specific EGF kinase inhibitors, which are already commercially available for cancer patients. The ultimate goal of the present proposal is to prepare to step from bench to bedside and establish a novel therapeutic approach to treat some rare forms of glomerular diseases effectively and specifically.

E-Rare 2012 - Created by Toussaint Biger